Sustained HIV-1 suppression in treatment-naive patients undergoing 4- to 3-drug induction maintenance therapy (INDUMAIN) [1]

Journal of Acquired Immune Deficiency Syndromes

Volumn 33, Issue 4, 2003, Pages 543-544

  Michelmore, Harry ^a   Jeganathan, Sarangapany ^a   Chan, Derek ^a   Batterham, Marijka ^a,b  

^a Albion Street Centre ^*  (Australia)

^b UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DIARRHEA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; LETTER; LIPOATROPHY; NEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RASH;

EID: 0037622823     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200308010-00017     Document Type: Letter

References (14)

1. Yeni PG, Hammer SM, Carpenter CCJ, et al. Antiretroviral treatment for adult HIV infection in 2002, updated recommendations of the International AIDS Society-USA Panel. JAMA. 2002;288: 222-235.
2. Mocroft A, Youle M, Moore A, et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS. 2001;15:185-194.
3. Raboud JM, Julio SG, Conway B, et al. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS. 1998;12:1619-1624.
4. Pilcher DC, Miller WC, Beatty ZA, et al. Detectable HIV-I RNA at levels below quantifiable limits by Amplicor HIV-1 Monitor is associated with virologic relapse on antiretroviral therapy. AIDS. 1999;13:1337-1342.
5. Newcombe R. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17:857-872.
6. Reijers MH, Weverling GJ, Jurriaans S, et al. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet. 1998;352:185-190.
7. Havlir DV, Marschner IC, Hirsch MS, et al. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. N Engl J Med. 1998; 339:1261-1268.
8. Pialoux G, Raffi F, Brun-Vezinet F, et al. A randomized trial of three maintenance regimens after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. N Engl J Med. 1998;339:1269-1276.
9. Clumeck N, Mundere J, Kabeya K, et al. MIRO: a randomized trial of maintenance therapy with or without protease inhibitors after 4 months of triple or quadruple therapy. 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, IL.
10. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons infected with human immunodeficiency virus infection and CD4 counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725-733.
11. Kempf DJ, Rode RA, Xu Y, et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS. 1998;12:F9-F14.
12. Moyle G, Pozniak A, Opravil M, et al. The SPICE study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues. Study of protease inhibitors in Europe. JAIDS. 2000;23:128-137.
13. Ruiz L, van Lunzen J, Arno A, et al. Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue. AIDS. 1999;13:F1-F8.
14. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med. 1999;340:1605-1613.